Proya Cosmetics Co.,Ltd.

SHSE:603605 Stock Report

Market Cap: CN¥36.4b

Proya CosmeticsLtd Valuation

Is 603605 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 603605 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 603605 (CN¥92.3) is trading below our estimate of fair value (CN¥170.79)

Significantly Below Fair Value: 603605 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 603605?

Key metric: As 603605 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 603605. This is calculated by dividing 603605's market cap by their current earnings.
What is 603605's PE Ratio?
PE Ratio25.1x
EarningsCN¥1.45b
Market CapCN¥36.37b

Price to Earnings Ratio vs Peers

How does 603605's PE Ratio compare to its peers?

The above table shows the PE ratio for 603605 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average32.9x
300957 Yunnan Botanee Bio-Technology GroupLTD
35.3x33.3%CN¥20.9b
300146 Byhealth
30.5x34.8%CN¥21.7b
003006 Chongqing Baiya Sanitary Products
38.8x26.1%CN¥11.4b
603868 Shanghai Flyco Electrical Appliance
27.2x16.0%CN¥17.9b
603605 Proya CosmeticsLtd
25.1x20.4%CN¥36.4b

Price-To-Earnings vs Peers: 603605 is good value based on its Price-To-Earnings Ratio (25.1x) compared to the peer average (32.9x).

Price to Earnings Ratio vs Industry

How does 603605's PE Ratio compare vs other companies in the CN Personal Products Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
603605 25.1xIndustry Avg. 34.7xNo. of Companies5PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 603605 is good value based on its Price-To-Earnings Ratio (25.1x) compared to the CN Personal Products industry average (34.7x).

Price to Earnings Ratio vs Fair Ratio

What is 603605's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

603605 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio25.1x
Fair PE Ratio29.9x

Price-To-Earnings vs Fair Ratio: 603605 is good value based on its Price-To-Earnings Ratio (25.1x) compared to the estimated Fair Price-To-Earnings Ratio (29.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 603605 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥92.30
CN¥130.22
+41.1%
11.1%CN¥161.00CN¥107.50n/a20
Nov ’25CN¥97.24
CN¥130.69
+34.4%
11.0%CN¥164.00CN¥107.50n/a20
Oct ’25CN¥110.09
CN¥130.20
+18.3%
10.9%CN¥164.00CN¥108.40n/a20
Sep ’25CN¥95.50
CN¥131.02
+37.2%
11.1%CN¥169.00CN¥108.40n/a20
Aug ’25CN¥87.47
CN¥137.05
+56.7%
12.1%CN¥178.00CN¥109.00n/a20
Jul ’25CN¥107.68
CN¥137.25
+27.5%
10.9%CN¥172.00CN¥109.00n/a20
Jun ’25CN¥108.89
CN¥135.44
+24.4%
11.2%CN¥172.00CN¥103.00n/a20
May ’25CN¥109.49
CN¥134.00
+22.4%
12.1%CN¥172.00CN¥103.00n/a20
Apr ’25CN¥96.07
CN¥134.08
+39.6%
12.9%CN¥165.00CN¥103.00n/a19
Mar ’25CN¥101.60
CN¥139.17
+37.0%
15.0%CN¥200.00CN¥104.00n/a18
Feb ’25CN¥79.53
CN¥140.34
+76.5%
14.5%CN¥200.00CN¥104.00n/a18
Jan ’25CN¥99.40
CN¥142.78
+43.6%
12.3%CN¥200.00CN¥123.00n/a18
Dec ’24CN¥100.09
CN¥143.61
+43.5%
12.0%CN¥200.00CN¥123.00n/a18
Nov ’24CN¥106.09
CN¥145.50
+37.1%
11.2%CN¥200.00CN¥123.00CN¥97.2418
Oct ’24CN¥101.60
CN¥147.55
+45.2%
10.2%CN¥199.00CN¥130.50CN¥110.0918
Sep ’24CN¥111.12
CN¥150.76
+35.7%
13.2%CN¥204.00CN¥130.50CN¥95.5018
Aug ’24CN¥112.89
CN¥154.00
+36.4%
15.8%CN¥234.00CN¥131.00CN¥87.4719
Jul ’24CN¥112.40
CN¥154.74
+37.7%
14.7%CN¥226.00CN¥133.00CN¥107.6818
Jun ’24CN¥119.86
CN¥148.36
+23.8%
4.7%CN¥164.94CN¥141.00CN¥108.8918
May ’24CN¥119.93
CN¥148.62
+23.9%
4.8%CN¥164.94CN¥140.71CN¥109.4917
Apr ’24CN¥129.89
CN¥141.86
+9.2%
6.0%CN¥157.14CN¥125.71CN¥96.0717
Mar ’24CN¥128.43
CN¥141.49
+10.2%
5.9%CN¥157.14CN¥125.71CN¥101.6018
Feb ’24CN¥116.56
CN¥140.06
+20.2%
5.4%CN¥152.86CN¥125.71CN¥79.5318
Jan ’24CN¥119.63
CN¥138.10
+15.4%
8.3%CN¥152.86CN¥102.14CN¥99.4018
Dec ’23CN¥123.64
CN¥138.10
+11.7%
8.3%CN¥152.86CN¥102.14CN¥100.0918
Nov ’23CN¥122.02
CN¥136.83
+12.1%
8.3%CN¥152.86CN¥102.14CN¥106.0919

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

SYoung Group

CN¥5.0b

Engages in the research and development, production, and sale of cosmetic products in China.

300740

CN¥12.82

7D

-7.7%

1Y

-19.4%

Sirio Pharma

CN¥6.2b

Operates as a contract manufacturer for dietary supplement industry worldwide.

300791

CN¥26.60

7D

-5.6%

1Y

2.7%

Byhealth

CN¥21.7b

Develops and sells dietary supplements.

300146

CN¥12.90

7D

-5.4%

1Y

-28.4%